ReviewCurrent treatment options in oncology2026
The Future is Local: the Role of Decentralised Clinical Trials in Patients with Advanced Cancer Receiving Palliative Care.
Review in Current treatment options in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementTrial participation is increasingly recognised as a crucial component of optimal cancer care, yet patients with advanced cancer receiving palliative care often face significant challenges in meeting the logistical demands of traditional clinical trials. Decentralised clinical trials (DCTs), including teletrials, which conduct study activities outside a central site - frequently in participant's homes or local communities - offer a promising model to overcome these barriers. By enabling remote participation, DCTs can overcome geographical and functional barriers, making trials more accessible to this often-frail population. However, there are important concerns that warrant careful consideration. DCTs may inadvertently fragment care, expose vulnerable patients to novel medications in an isolated setting, and exacerbate digital health inequities. In our experience these challenges can be mitigated through careful trial selection, as well as the implementation of rigorous screening and support systems to ensure both patient suitability and continuity of care. Key measures include close liaison with treating oncologists and palliative care teams, 24/7 clinical phone support, accessible IT assistance during working hours, and collaboration with local trial coordinators when available. This approach not only extends the geographical reach of clinical trial participation for patients with advanced cancer receiving palliative care, but also maintains trial rigour and patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.